foxo4-dri clinical trial nct eXoZymes (Nasdaq: EXOZ) is targeting metabolic dysfunction a layer deeper than appetite. In a recent Webull webinar, Chief Commercial Officer Damien Perriman walked investors through NCT, the company's first proof point. eXoZymes FOXO4-DRI induces keloid senescent fibroblast
Description
This covers the administration only
Hoffman & Cook, 2006)
Therefore, its unknown whether its necessary to cycle DSIP
doi: 10.1016/j.archger.2010.10.004
